Drug distributor

The U.S. government on Tuesday filed its first criminal charges against a major drug distributor and company executives over their alleged roles in fueling the nation’s opioid epidemic by putting profits ahead of patients’ safety. Rochester Drug Co-operative Inc (RDC); one of the 10 largest U.S. drug distributors; agreed to pay a $20 million fine and enter a five-year deferred prosecution agreement to resolve charges it turned a blind eye to thousands of suspicious orders for opioids.
Another former executive, compliance chief William Pietruszewski, 53, of Oak Ridge, New Jersey; pleaded guilty to three criminal counts and agreed to cooperate with prosecutors. The case marks a new U.S. effort to curtail the growing number of addictions to opioids; including oxycodone and other prescription painkillers.

The prescription of painkillers

Opioids, including prescription painkillers and heroin; played a role in a record 47,600 U.S. overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention. “This country is in the midst of a prescription drug abuse epidemic,” U.S. Attorney Geoffrey Berman said at a Manhattan news conference. “This epidemic has driven by greed. As alleged, Doud cared more about profits than the laws intended to protect human life.”

Hundreds of lawsuits by state and local governments accuse drugmakers such as Purdue Pharma of deceptively marketing opioids; distributors such as AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp of ignoring that they being diverted for improper uses. These defendants, as well as RDC; among those named last month in a lawsuit by New York Attorney General Letitia James alleging widespread fraud.

The red flags

In Tuesday’s settlement, RDC admitted to violating narcotics laws from January 2012 to March 2017; by distributing oxycodone, fentanyl, and other controlled substances to pharmacy customers despite internal “red flags” that they would be used improperly. Berman said the red flags included dramatic increases in order sizes, pharmacy customers paying in cash, and prescriptions filled by doctors under investigation by law enforcement or on an RDC “watch list.”
Prosecutors said RDC identified about 8,300 potentially suspicious “orders of interest,” including for oxycodone; from 2012 to 2016, but reported just four to the federal Drug Enforcement Administration. Berman said this lax oversight enabled RDC to boost sales of oxycodone tablets more than 800 % and fentanyl dosages roughly 2,000 percent over that period, while Doud’s pay more than doubled, to more than $1.5 million.
“RDC was, in Doud’s own words, the knight in shining armor for pharmacies that had cut off by other distributors,” Berman said. The deferred prosecution agreement allows RDC to keep operating, subject to three years of independent compliance monitoring, and avoid prosecution if it complies with the terms.